WuXi Biologics (Cayman) Inc.
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from WuXi Biologics (Cayman) Inc.'s yearly results (2022–2025), compared with companies in China. Tap ? on any ratio for what it means.
What stands out
- Cash Locked Ratio: For every ¥100 of sales, ¥23 is tied up in day-to-day operations (money owed by customers + stock − money owed to suppliers), against ¥19 tied up three years earlier. More money tied up than 91% of companies in China.
Where ¥100 of sales goes
Latest year (Dec 2025). Taxes and other income are not shown, so the parts need not add up to 100.
Cash quality
Profit Cash Ratio
¥139Over the last 3 years, every ¥100 of reported profit came with ¥139 of operating cash.
Lower than 70% of companies in China.
Self-Funding Ratio
1.4×Over the last 3 years its own operating cash covered its investment spending (capex) 1.4 times.
Lower than 81% of companies in China.
Cash Locked Ratio
¥23For every ¥100 of sales, ¥23 is tied up in day-to-day operations (money owed by customers + stock − money owed to suppliers), against ¥19 tied up three years earlier.
More money tied up than 91% of companies in China.
Growth quality
Steadiness Ratio
3/3 · 1/3Sales grew in 3 of the last 3 years; profit grew in 1 of 3.
Less steady than 64% of companies in China.
Growth Efficiency Ratio
¥7Sales grew 43% in 3 years; of every extra ¥100 of sales, ¥7 became extra profit.
Lower than 75% of companies in China.
Asset Productivity Ratio
+43% / +29%In 3 years sales changed by +43% while total assets changed by +29%. Sales grew faster than assets.
Balance-sheet strength
Debt Due Cover Ratio
7.3×Debt due within a year is covered 7.3 times by its yearly operating cash.
Higher than 72% of companies in China.
Cash Cushion Ratio
—Data incomplete
Tangible Assets Ratio
97%Of every ¥100 the company owns, ¥97 is in tangible assets such as plants, cash, stock and receivables; the rest is goodwill and other intangibles.
Less tangible than 51% of companies in China.
Tangible Net Worth Ratio
96%Of every ¥100 of net worth, ¥96 is tangible; the rest is goodwill and other intangibles, often from buying other companies.
More tangible than 58% of companies in China.
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (13)
WuXi Biologics (Cayman) Inc. owes ¥0.17 for every ¥1 it owns. Net profit rose 46% in the year to Dec 2025, and grew 4% a year on average over 3 years.
Compared with companies in China · latest annual results Dec 2025.
P/E ratio
37.1Investors pay ¥37.1 for every ¥1 of WuXi Biologics (Cayman) Inc.'s yearly profit, higher than 91% of companies in China.
P/B ratio
3.35The share price is 3.35 times WuXi Biologics (Cayman) Inc.'s book value per share, higher than 80% of companies in China.
Market cap
HK$186.3 BThe total market value of all of WuXi Biologics (Cayman) Inc.'s shares at today's price (share price × number of shares), larger than 50% of companies in China. PosiCap size class: Tito Cap.
Net worth (book value)
¥47.2 BWhat WuXi Biologics (Cayman) Inc. would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (31 Dec 2025).
Return on equity (ROE)
11.4%WuXi Biologics (Cayman) Inc. earned 11.4% on its shareholders' money over the last year, lower than 57% of companies in China.
Owes vs Owns
0.17×WuXi Biologics (Cayman) Inc. owes ¥0.17 for every ¥1 it owns (low), lower than 97% of companies in China.
Dividend yield
NoneWuXi Biologics (Cayman) Inc. does not currently pay a dividend.
Revenue growth
+17%Revenue rose 17% in the year to Dec 2025, and grew 13% a year on average over 3 years.
Profit growth
+46%Net profit rose 46% in the year to Dec 2025, and grew 4% a year on average over 3 years.
Profit margin
22.5%WuXi Biologics (Cayman) Inc. keeps ¥23 of every ¥100 of revenue as net profit.
Cash quality
1.3×Cash from WuXi Biologics (Cayman) Inc.'s business was 1.3× its reported profit in the year to Dec 2025 — its profit turned into cash.
Interest cover
49.3×WuXi Biologics (Cayman) Inc.'s operating profit covered its interest costs 49.3 times in the year to Dec 2025.
Cash vs debt
Net cashWuXi Biologics (Cayman) Inc. held ¥12.6 B more cash than debt (net cash) at Dec 2025.
Questions
What is WuXi Biologics (Cayman) Inc.'s P/E ratio?
Investors pay ¥37.1 for every ¥1 of WuXi Biologics (Cayman) Inc.'s yearly profit, higher than 91% of companies in China.
What is WuXi Biologics (Cayman) Inc.'s return on equity?
WuXi Biologics (Cayman) Inc. earned 11.4% on its shareholders' money over the last year, lower than 57% of companies in China.
How much does WuXi Biologics (Cayman) Inc. owe compared with what it owns?
WuXi Biologics (Cayman) Inc. owes ¥0.17 for every ¥1 it owns (low), lower than 97% of companies in China.
Does WuXi Biologics (Cayman) Inc. pay a dividend?
No. WuXi Biologics (Cayman) Inc. does not currently pay a dividend.
Is WuXi Biologics (Cayman) Inc.'s revenue growing?
Revenue rose 17% in the year to Dec 2025, and grew 13% a year on average over 3 years.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.